Supernus Pharmaceuticals announced it will report Q1 2026 financial and business results after market close on May 5, 2026, followed by a conference call at 4:30 p.m. ET.
Key takeaways
Q1 2026 results to be released after market close on May 5, 2026.
Conference call and webcast hosted by CEO Jack Khattar and CFO Tim Dec at 4:30 p.m. ET on May 5, 2026.
Live webcast available at www.supernus.com/investors with replay for 60 days.
Pre-registration available for dial-in with personalized conference code.
Company focuses on CNS diseases including ADHD, Parkinson's, epilepsy, and migraine.